{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:02:16Z","timestamp":1778212936654,"version":"3.51.4"},"reference-count":43,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.3209","type":"journal-article","created":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T12:32:18Z","timestamp":1620477138000},"page":"e213209","source":"Crossref","is-referenced-by-count":18,"title":["Association of Low-Dose Quetiapine and Diabetes"],"prefix":"10.1001","volume":"4","author":[{"given":"Mikkel","family":"H\u00f8jlund","sequence":"first","affiliation":[{"name":"Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark"},{"name":"Department of Psychiatry Aabenraa, Mental Health Services in the Region of Southern Denmark, Aabenraa, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars C.","family":"Lund","sequence":"additional","affiliation":[{"name":"Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kjeld","family":"Andersen","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Psychiatry, University of Southern Denmark, Odense, Denmark"},{"name":"Department of Psychiatry Odense, Mental Health Services in the Region of Southern Denmark, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[{"name":"The Zucker Hillside Hospital, Department of Psychiatry, Zucker School of Medicine at Hofstra\/Northwell, New York, New York"},{"name":"Department of Child and Adolescent Psychiatry, Charit\u00e9 Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper","family":"Hallas","sequence":"additional","affiliation":[{"name":"Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"issue":"10","key":"zoi210113r3","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.euroneuro.2017.07.001","article-title":"International trends in antipsychotic use: a study in 16 countries, 2005-2014.","volume":"27","author":"H\u00e1lfd\u00e1narson","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"zoi210113r4","doi-asserted-by":"publisher","first-page":"E225","DOI":"10.9778\/cmajo.20140009","article-title":"Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study.","volume":"2","author":"Pringsheim","year":"2014","journal-title":"CMAJ Open"},{"issue":"3","key":"zoi210113r5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010861","article-title":"Quetiapine use in adults in the community: a population-based study in Alberta, Canada.","volume":"6","author":"Duncan","year":"2016","journal-title":"BMJ Open"},{"issue":"12","key":"zoi210113r6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006135","article-title":"Prescribing of antipsychotics in UK primary care: a cohort study.","volume":"4","author":"Marston","year":"2014","journal-title":"BMJ Open"},{"issue":"9","key":"zoi210113r7","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00228-017-2281-8","article-title":"The antipsychotic agent quetiapine is increasingly not used as such: dispensed prescriptions in Norway 2004-2015.","volume":"73","author":"Gjerden","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"zoi210113r8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.","volume":"8","author":"De Hert","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"zoi210113r9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11892-019-1220-8","article-title":"Association Between Antipsychotic Medication Use and Diabetes.","volume":"19","author":"Holt","year":"2019","journal-title":"Curr Diab Rep"},{"issue":"10","key":"zoi210113r10","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1001\/jamapsychiatry.2013.2053","article-title":"Antipsychotics and the risk of type 2 diabetes mellitus in children and youth.","volume":"70","author":"Bobo","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"zoi210113r11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/wps.20187","article-title":"Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study.","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"issue":"1","key":"zoi210113r12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/1471-244X-11-197","article-title":"Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?","volume":"11","author":"Ulcickas Yood","year":"2011","journal-title":"BMC Psychiatry"},{"issue":"6","key":"zoi210113r13","doi-asserted-by":"publisher","first-page":"308","DOI":"10.9740\/mhc.2016.11.308","article-title":"Evaluation of the use of low-dose quetiapine and the risk of metabolic consequences: A retrospective review.","volume":"6","author":"Carr","year":"2016","journal-title":"Ment Health Clin"},{"key":"zoi210113r14","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/S0924-9338(10)71701-6","article-title":"From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics.","volume":"25","author":"Correll","year":"2010","journal-title":"Eur Psychiatry"},{"issue":"10","key":"zoi210113r15","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.euroneuro.2015.07.010","article-title":"Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: a pharmacoepidemiological-pharmacodynamic study in VigiBase.","volume":"25","author":"Montastruc","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"zoi210113r17","doi-asserted-by":"publisher","first-page":"k3532","DOI":"10.1136\/bmj.k3532","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE).","volume":"363","author":"Langan","year":"2018","journal-title":"BMJ"},{"issue":"2","key":"zoi210113r18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrendo.2014.203","article-title":"Diabetes mellitus and severe mental illness: mechanisms and clinical implications.","volume":"11","author":"Holt","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"45","key":"zoi210113r19","first-page":"112","article-title":"Does emotional stress cause type 2 diabetes mellitus? a review from the European Depression in Diabetes (EDID) Research Consortium.","volume":"9","author":"Pouwer","year":"2010","journal-title":"Discov Med"},{"issue":"2","key":"zoi210113r20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/wps.v14.2","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"issue":"7","key":"zoi210113r21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1403494810394717","article-title":"The Danish National Prescription Registry.","volume":"39","author":"Kildemoes","year":"2011","journal-title":"Scand J Public Health"},{"issue":"7","key":"zoi210113r22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/1403494811401482","article-title":"The Danish National Patient Register.","volume":"39","author":"Lynge","year":"2011","journal-title":"Scand J Public Health"},{"issue":"7","key":"zoi210113r23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1403494810387965","article-title":"The Danish Civil Registration System.","volume":"39","author":"Pedersen","year":"2011","journal-title":"Scand J Public Health"},{"key":"zoi210113r24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2147\/CLEP","article-title":"The Danish health care system and epidemiological research: from health care contacts to database records.","volume":"11","author":"Schmidt","year":"2019","journal-title":"Clin Epidemiol"},{"issue":"4","key":"zoi210113r26","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","article-title":"High-dimensional propensity score adjustment in studies of treatment effects using health care claims data.","volume":"20","author":"Schneeweiss","year":"2009","journal-title":"Epidemiology"},{"issue":"25","key":"zoi210113r27","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"4","key":"zoi210113r28","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology.","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"1","key":"zoi210113r30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11920-010-0165-z","article-title":"Diabetes and depression.","volume":"13","author":"Campayo","year":"2011","journal-title":"Curr Psychiatry Rep"},{"issue":"10","key":"zoi210113r31","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.2337\/dc13-0560","article-title":"Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review.","volume":"36","author":"Barnard","year":"2013","journal-title":"Diabetes Care"},{"issue":"7","key":"zoi210113r32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182088","article-title":"The risk of new-onset diabetes in antidepressant users - a systematic review and meta-analysis.","volume":"12","author":"Salvi","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"zoi210113r33","doi-asserted-by":"publisher","first-page":"460","DOI":"10.4088\/JCP.10m06822","article-title":"Prediabetes in patients treated with antipsychotic drugs.","volume":"73","author":"Manu","year":"2012","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"zoi210113r34","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1111\/bcp.v85.7","article-title":"Trends in utilization and dosing of antipsychotic drugs in Scandinavia: comparison of 2006 and 2016.","volume":"85","author":"H\u00f8jlund","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"zoi210113r35","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.archger.2017.01.006","article-title":"Glucose monitoring in new users of second-generation antipsychotics in older people.","volume":"70","author":"Ndukwe","year":"2017","journal-title":"Arch Gerontol Geriatr"},{"issue":"17","key":"zoi210113r36","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.2146\/ajhp150150","article-title":"Screening for diabetes in patients receiving second-generation atypical antipsychotics.","volume":"72","author":"Hinds","year":"2015","journal-title":"Am J Health Syst Pharm"},{"issue":"6","key":"zoi210113r37","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1176\/appi.ps.201400222","article-title":"Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.","volume":"66","author":"Connolly","year":"2015","journal-title":"Psychiatr Serv"},{"issue":"1","key":"zoi210113r38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"zoi210113r39","doi-asserted-by":"publisher","first-page":"k1951","DOI":"10.1136\/bmj.k1951","article-title":"Antidepressant utilisation and incidence of weight gain during 10 years\u2019 follow-up: population based cohort study.","volume":"361","author":"Gafoor","year":"2018","journal-title":"BMJ"},{"issue":"5","key":"zoi210113r40","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20180967","article-title":"The effect of selective serotonin re-uptake inhibitors on risk of type II diabetes mellitus and acute pancreatitis: a meta-analysis.","volume":"38","author":"Yao","year":"2018","journal-title":"Biosci Rep"},{"issue":"1","key":"zoi210113r41","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1001\/jamapsychiatry.2020.2762","article-title":"Association of selective serotonin reuptake inhibitors with the risk of type 2 diabetes in children and adolescents.","volume":"78","author":"Sun","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"zoi210113r42","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/jamapsychiatry.2015.2923","article-title":"Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis.","volume":"73","author":"Galling","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"zoi210113r43","doi-asserted-by":"publisher","first-page":"e150285","DOI":"10.1001\/jamapediatrics.2015.0285","article-title":"Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths.","volume":"169","author":"Rubin","year":"2015","journal-title":"JAMA Pediatr"},{"key":"zoi210113r16","volume-title":"Stahl\u2019s Essential Psychopharmacology: Neuroscientific Basis and Practical Application","author":"Stahl","year":"2013","edition":"4th ed"},{"key":"zoi210113r29","volume-title":"Sygdomsbyrden i Danmark - Sygdomme","author":"Flachs","year":"2015"},{"key":"zoi210113r1","unstructured":"U.S. Food and Drug Administration. SEROQUEL XR\u00ae (quetiapine fumarate) extended-release tablets. Accessed March 23, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/022047s043lbl.pdf"},{"key":"zoi210113r2","unstructured":"European Medicines Agency. Seroquel, Seroquel XR and associated names (quetiapine) - summary of product characteristics. Accessed March 23, 2020. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/seroquel-seroquel-xr-associated-names-article-30-referral-annex-iii_en.pdf"},{"key":"zoi210113r25","unstructured":"The Danish Health Data Authority. Medstat.dk (Register of Medicinal Product Statistics). Accessed February 19, 2020. https:\/\/medstat.dk\/en"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2779687\/hjlund_2021_oi_210113_1623094168.17136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T15:03:37Z","timestamp":1623769417000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2779687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,7]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.3209","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,7]]}}}